Simple blood test may predict prostate cancer radiation risks

NCT ID NCT07145437

Not yet recruiting Diagnosis Sponsor: Clinique Sainte Clotilde Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a blood test, called the RILA assay, can predict which prostate cancer patients will have late side effects from a precise type of radiation therapy (SBRT). About 220 men with low- or intermediate-risk prostate cancer will give a blood sample before treatment and be followed for 5 years. The goal is to personalize treatment and reduce severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radio-induced Lymphocyte Apoptosis (RILA) Assay
What this could lead to: If successful, this blood test could help doctors identify which prostate cancer patients are at higher risk for side effects from radiation, allowing for more personalized and safer treatment plans.
What could go wrong: This is an early-stage study focused on prediction, not treatment. The test may not accurately predict side effects in all patients, and results may not change outcomes directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.